08/12/22 11:00 AMNasdaq : SNY Public health experts underscore importance of flu vaccinations to help reduce health inequities among high-risk populationsVaccine fatigue may continue to be a barrier to the upcoming flu season Black Americans are less likely to get a flu vaccine compared to white Americans, increasing risk of flu-related complications or hospitalizations 1 People over 65 account for majority of flu-related hospitalizations and deathsRHEA-AInegative
08/12/22 9:05 AMNasdaq : SNY clinical trialNIHR and Sanofi Announce First Patient Enrolled in Large European Clinical Study to Investigate Protection Against RSV, the Leading Cause of Infant Hospitalisation WorldwideSanofi and the National Institute for Health and Care Research have today announced that the first patient has been enrolled in the H ospit a lised R SV Mon oclonal Ant i body Pr e vention study. The study has been developed as a collaboration between NIHR, investigators, Sanofi and its clinical research organisation partner, Labcorp. More than 20,000 infants...RHEA-AIneutral
08/03/22 2:53 PMNasdaq : SNY managementSanofi appoints new Heads of U.S. General Medicines, and North America Vaccines and Consumer HealthcareSanofi announces three appointments to key leadership roles for U.S. General Medicines and its North American Vaccines and Consumer Healthcare businesses.Olivier Bogillot becomes Head of U.S. General Medicines. Bogillot, most recently President ofRHEA-AIneutral
07/26/22 7:00 AMNasdaq : SNY partnershipSanofi partners with Howard University in an unprecedented pharmacy fellowship programAs part of its ongoing efforts to address disparities in underrepresented communities, Sanofi has announced a collaboration with Howard University College of Pharmacy for a two-year post-professional Doctorate in Pharmacy fellowship program. Sanofi'sRHEA-AIvery positive
07/01/22 5:04 PMNasdaq : SNY Sanofi flu vaccines licensed and approved for 2022-2023 influenza season, including CDC preferred higher-dose vaccines for adults 65+* Fluzone ® High-Dose Quadrivalent (Influenza Vaccine) and Flublok ® Quadrivalent (Influenza Vaccine) are the only two flu vaccines proven to help prevent more cases of flu in older adults, compared to their standard-dose flu vaccine comparators as assessed in randomized controlled trials, theRHEA-AIneutral
06/07/22 4:44 PMNasdaq : SNY, REGN fda approvalFDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic DermatitisChildren treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, experienced significantly improved overall disease severity and significantly reduced itch compared to TCS alone at week 16 in a Phase 3 trialLong-term safety data from a 52-week open-label extension trial inRHEA-AIneutral
06/07/22 8:30 AMNasdaq : SNY Sanofi unveils new 900,000-square-foot campus at Cambridge Crossing2,500 Sanofi Massachusetts-based employees come together in a shared space to improve collaboration while growing our science-centered, patient-focused culture Single integrated campus supports Play to Win strategy to focus on growth, lead with innovation, accelerate efficiencies, and reinvent theRHEA-AIvery positive
05/31/22 12:59 AMNasdaq : REGN, SNY FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo NodularisDupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approvedRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug AdministrationRHEA-AIneutral
05/20/22 3:15 PMNasdaq : REGN, SNY fda approvalFDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic EsophagitisDupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA's Priority Review action dateDupixent 300 mg weekly significantly improved signs andRHEA-AIpositive
04/13/22 5:00 AMNasdaq : SNY Sempre Health Improved Medication Adherence by 25% for Diabetes Patients Prescribed Sanofi MedicationsToday, Sempre Health announced compelling outcomes achieved during the first year of its collaboration with Sanofi (Nasdaq: SNY), an innovative global healthcareRHEA-AIpositive